Related Experiment Videos
Drug resistance in multiple myeloma
1Department of Hematology, University Hospital Rotterdam Dijkzigt, The Netherlands.
Pathologie-Biologie
|April 8, 1999
Summary
Multidrug resistance (MDR) in multiple myeloma (MM) hinders treatment. Non-cytotoxic agents show potential for reversing MDR by inhibiting P-glycoprotein, improving chemotherapy effectiveness.
Area of Science:
- Oncology
- Pharmacology
Background:
- Multidrug resistance (MDR) presents a significant challenge in treating multiple myeloma (MM).
- MDR involves resistance to various chemotherapy drugs, often mediated by proteins like P-glycoprotein (Pgp) and Lung Resistance Protein (LRP).
Purpose of the Study:
- To explore the potential of non-cytotoxic agents in reversing MDR in multiple myeloma.
- To investigate the impact of MDR reversal on the pharmacokinetics of chemotherapeutic agents.
Main Methods:
- Review of recent clinical phase I/II trials investigating MDR reversal agents.
- Analysis of P-glycoprotein inhibition and its effects on tumor cells and drug pharmacokinetics.
Main Results:
- Preliminary results indicate that MDR reversal is achievable using agents like verapamil, cyclosporin A, and PSC 833 (Valdospar).
- MDR reversal may alter the plasma pharmacokinetics of cytostatic agents.
Conclusions:
- Reversal of MDR through P-glycoprotein inhibition offers a promising strategy to overcome treatment resistance in multiple myeloma.
- Further investigation into P-glycoprotein reversal has significant implications for enhancing MM therapy.